Revance Therapeutics Inc

NASDAQ:RVNC 4:00:00 PM EDT

34.64

+0.22 (+0.64%)

: $33.83 -0.81 (-2.34%)

Market Cap (Intraday)	2.87B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$37.04 Million
Adjusted EPS	-$0.81

See more estimates

10-Day MA	$33.88
50-Day MA	$25.45
200-Day MA	$20.94

See more pivots

Revance Therapeutics Inc Stock, NASDAQ:RVNC

1222 Demonbreun Street, Suite 1001, Nashville, Tennessee 37203

United States of America

Phone: +1.615.724.7755

Number of Employees: 495

http://www.revance.com

Description

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.